1. Home
  2. CCIA vs SCLXW Comparison

CCIA vs SCLXW Comparison

Compare CCIA & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCIA
  • SCLXW
  • Stock Information
  • Founded
  • CCIA N/A
  • SCLXW N/A
  • Country
  • CCIA
  • SCLXW United States
  • Employees
  • CCIA N/A
  • SCLXW N/A
  • Industry
  • CCIA
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCIA
  • SCLXW Health Care
  • Exchange
  • CCIA Nasdaq
  • SCLXW Nasdaq
  • Market Cap
  • CCIA N/A
  • SCLXW N/A
  • IPO Year
  • CCIA 2023
  • SCLXW N/A
  • Fundamental
  • Price
  • CCIA $26.21
  • SCLXW $0.18
  • Analyst Decision
  • CCIA
  • SCLXW
  • Analyst Count
  • CCIA 0
  • SCLXW 0
  • Target Price
  • CCIA N/A
  • SCLXW N/A
  • AVG Volume (30 Days)
  • CCIA N/A
  • SCLXW 4.0K
  • Earning Date
  • CCIA N/A
  • SCLXW 03-07-2025
  • Dividend Yield
  • CCIA N/A
  • SCLXW N/A
  • EPS Growth
  • CCIA N/A
  • SCLXW N/A
  • EPS
  • CCIA N/A
  • SCLXW N/A
  • Revenue
  • CCIA N/A
  • SCLXW $55,152,000.00
  • Revenue This Year
  • CCIA N/A
  • SCLXW N/A
  • Revenue Next Year
  • CCIA N/A
  • SCLXW N/A
  • P/E Ratio
  • CCIA N/A
  • SCLXW N/A
  • Revenue Growth
  • CCIA N/A
  • SCLXW 22.02
  • 52 Week Low
  • CCIA N/A
  • SCLXW $0.18
  • 52 Week High
  • CCIA N/A
  • SCLXW $0.18
  • Technical
  • Relative Strength Index (RSI)
  • CCIA 50.19
  • SCLXW N/A
  • Support Level
  • CCIA $26.14
  • SCLXW N/A
  • Resistance Level
  • CCIA $26.50
  • SCLXW N/A
  • Average True Range (ATR)
  • CCIA 0.13
  • SCLXW 0.00
  • MACD
  • CCIA -0.04
  • SCLXW 0.00
  • Stochastic Oscillator
  • CCIA 12.18
  • SCLXW 0.00

About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: